AP2007004059A0 - Compositions for immunizing against mycobacterium - Google Patents

Compositions for immunizing against mycobacterium

Info

Publication number
AP2007004059A0
AP2007004059A0 AP2007004059A AP2007004059A AP2007004059A0 AP 2007004059 A0 AP2007004059 A0 AP 2007004059A0 AP 2007004059 A AP2007004059 A AP 2007004059A AP 2007004059 A AP2007004059 A AP 2007004059A AP 2007004059 A0 AP2007004059 A0 AP 2007004059A0
Authority
AP
ARIPO
Prior art keywords
compositions
against mycobacterium
immunizing against
immunizing
mycobacterium
Prior art date
Application number
AP2007004059A
Other languages
English (en)
Inventor
Helen Mcshane
Ansar A Pathan
Adrian Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0500102.9A external-priority patent/GB0500102D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of AP2007004059A0 publication Critical patent/AP2007004059A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AP2007004059A 2005-01-05 2006-01-05 Compositions for immunizing against mycobacterium AP2007004059A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0500102.9A GB0500102D0 (en) 2005-01-05 2005-01-05 Method for generating a memory t cell response
US64980405P 2005-02-03 2005-02-03
PCT/GB2006/000023 WO2006072787A1 (en) 2005-01-05 2006-01-05 Compositions for immunizing against mycobacterium

Publications (1)

Publication Number Publication Date
AP2007004059A0 true AP2007004059A0 (en) 2007-08-31

Family

ID=36062509

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004059A AP2007004059A0 (en) 2005-01-05 2006-01-05 Compositions for immunizing against mycobacterium

Country Status (16)

Country Link
EP (1) EP1833507B1 (ru)
JP (2) JP2008526823A (ru)
KR (1) KR20070108518A (ru)
AP (1) AP2007004059A0 (ru)
AU (1) AU2006204382B2 (ru)
BR (1) BRPI0606165A2 (ru)
CA (1) CA2592756A1 (ru)
CY (1) CY1111549T1 (ru)
EA (1) EA012436B1 (ru)
HR (1) HRP20110402T1 (ru)
IL (2) IL184414A (ru)
MA (1) MA29244B1 (ru)
MX (1) MX2007008182A (ru)
NZ (1) NZ560468A (ru)
PL (1) PL1833507T3 (ru)
WO (1) WO2006072787A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817061B1 (en) * 2004-12-01 2011-07-27 Aeras Global Tuberculosis Vaccine Foundation Electroporation of mycobacterium and overexpression of antigens in mycobacteria
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010121618A1 (en) * 2009-04-24 2010-10-28 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
EP2548019A1 (en) * 2010-03-19 2013-01-23 Red Flag Diagnostics GmbH In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis
JP6333814B2 (ja) 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
JP6605480B2 (ja) * 2014-01-09 2019-11-13 トランスジェン・ソシエテ・アノニム ヘテロオリゴマーマイコバクテリア抗原の融合物
RU2665817C1 (ru) * 2017-10-25 2018-09-04 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Вакцина рекомбинантная противотуберкулезная и адъювант для нее
US20220144893A1 (en) * 2019-03-14 2022-05-12 Sanford Burnham Prebys Medical Discovery Institute Nanomolar peptides and derivatives to differentially modulate ephrin receptors

Also Published As

Publication number Publication date
AU2006204382A1 (en) 2006-07-13
MA29244B1 (fr) 2008-02-01
CA2592756A1 (en) 2006-07-13
EA012436B1 (ru) 2009-10-30
JP2008526823A (ja) 2008-07-24
IL217235A0 (en) 2012-01-31
EP1833507B1 (en) 2011-03-16
WO2006072787A8 (en) 2006-09-14
EA200701440A1 (ru) 2008-02-28
HRP20110402T1 (hr) 2011-07-31
WO2006072787A1 (en) 2006-07-13
EP1833507A1 (en) 2007-09-19
KR20070108518A (ko) 2007-11-12
NZ560468A (en) 2010-05-28
MX2007008182A (es) 2008-02-19
CY1111549T1 (el) 2015-08-05
AU2006204382B2 (en) 2011-05-12
IL184414A (en) 2012-01-31
PL1833507T3 (pl) 2011-08-31
IL184414A0 (en) 2007-10-31
BRPI0606165A2 (pt) 2009-06-02
JP2013010775A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
AP2436A (en) Immunogenic composition
AP2008004547A0 (en) Petsticidal compositions
GB0503337D0 (en) Compositions
IL186721A0 (en) Bioenhanced compositions
GB0526283D0 (en) Compositions
GB0526038D0 (en) Immunogenic composition
IL217235A0 (en) Compositions for immunizing against mycobacterium
IL186093A0 (en) Lignan-containing compositions
GB0501365D0 (en) Compositions
GB0524128D0 (en) Compositions
GB0502479D0 (en) Novel compositions
GB0502475D0 (en) Novel compositions
EP2227249A4 (en) IMPROVED IMMUNIZING COMPOSITION
ZA200709913B (en) Bioenhanced compositions
IL197146A0 (en) Composition for photoprotection
GB2442408B (en) Mycobacterium W as an adjuvant
GB0525321D0 (en) Novel compositions
GB0513069D0 (en) Immunogenic composition
GB0526282D0 (en) Compositions
GB2422150B (en) PVA-containing compositions
GB0524803D0 (en) Novel compositions
GB0501364D0 (en) Compositions
GB0506065D0 (en) Compositions
GB0513071D0 (en) Immunogenic composition
GB0508412D0 (en) Compositions for intestinal conditions